Core One Labs (COOL.C) announced their wholly-owned subsidiary, Akome Biotech, has begun the development of its patent-pending psychedelic drug formulation for the treatment of Alzheimer’s Disease. Akome’s “next-generation” psychedelic…
COOL
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological…
Core One Labs (COOL.C) announced they have reached a definitive share purchase agreement which will see it acquire all outstanding share capital of Akome Biotech. Akome Biotech’s goal is…
Core One Labs (COOL.C) announced they have entered into a letter of intent (LOI) with Lobe Sciences (LOBE.C) to explore the formation of a joint venture (JV) involving the…
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The…
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also…
Core One Labs (COOL.C) inked a letter of intent to pick up pharmaceuticals company, Akome Biotech today, according to a press release. Akome develops psychedelic-based drugs to treat rare…
Core One Labs (COOL.C) announced they have acquired the Ketamine Infusion Centers of Texas (KITC), a health and wellness clinic that provides ketamine infusion therapy. The acquisition provides…
Core One Labs (COOL.C) announced their wholly-owned subsidiary Rejuva Mental Health Clinic has retained Dr. Stephen Peach as their Lead Physisician. In this role, Dr. Peach will be…
Core One Labs (COOL.C) announced they filed an application to list its common shares on the Capital Market tier of The NASDAQ Stock Market. The Nasdaq exchange is…